MENU
ALLO
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Allogene Therapeutics (ALLO) Ownership - Who owns Allogene Therapeutics?
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
210 East Grand Avenue
Phone
+1 650 457-2700
Employees
233
Web
https://www.allogene.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
345.45M
P/E Ratio
N/A
Total Cash
292.48M
Projected Growth
N/A
Total Debt
90.76M
Revenue
22K
Risk (Beta)
1.05
Dividend Yield
N/A
Total Cash/Share
1.35
Total Debt/Equity
N/A
Revenue/Share
0.00 USD as % of share price
Fundamentals
ALLO
Capitalization
345M
P/E Ratio
N/A
Risk (Beta)
1.05
Dividend Yield
N/A
Total Cash
292M
Total Cash/Share
1.35
Total Debt
90.8M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.00%
Revenue
22K
ROE
N/A
Book Value
422M
P/B Ratio
0.82
Cash Flow
N/A
Earnings
-1.32
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
212K
Current Ratio
8.54
Current Revenue Per Employee
60.94
Dividends Per Share - Security
N/A
EBITDA
-243.33M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-43.24
Shares Held By Institutions
485M
Shares Outstanding - Current
217M
Total Liabilities
127M
Total Volume MTD
N/A
Value
-1
Gain YTD
-24.413
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a developer of allogeneic chimeric antigen receptor therapy
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
210 East Grand Avenue
Phone
+1 650 457-2700
Employees
233
Web
https://www.allogene.com